

**General Synthetic Scheme for the
Preparation of Compounds of Formula (I) wherein X is Absent**




Figure 1

General Synthetic Scheme for the Preparation of Intermediates Useful in the Preparation of Compounds of Formula (I) wherein X is CH₂




Figure 2

**General Synthetic Scheme for the
Preparation of Compounds of Formula (I) wherein X is CH₂**




Figure 3

**General Synthetic Scheme for the Preparation of
Certain Compounds of Formula (I) wherein X is CH₂ or CH₂CH₂**






Figure 4A

General Synthetic Scheme for the Preparation of Compounds of Formula (I)**Figure 4B**

General Synthetic Scheme for the Preparation of Compounds of Formula (I)**Figure 4C**




Figure 5

Effect of Compound 170 on Mean Arterial Pressure




Figure 6

PXRD of Compound 170; Example 2.5A




Figure 7

DSC of Compound 170; Example 2.5A




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13

DMS of Compound 170 Dihydrochloride




Figure 14




Figure 15

TGA of Compound 170 Dihydrochloride Hydrate




Figure 16





Figure 17

PXRD of Compound 170 Dihydrochloride Solvate; Example 2.8**Figure 18**

TGA of Compound 170 Dihydrochloride Solvate; Example 2.8




Figure 19




Figure 20




Figure 21

TGA of Compound 170 Sulfate Solvate; Example 2.9




Figure 22





Figure 23






Figure 25

Mas mRNA Expression Analysis by RT-PCR in Rat Heart




Figure 26

Cellular Expression of Mas in Coronary Arteries




Figure 27

Mas mRNA Expression Analysis by RT-PCR in Human Cardiovascular cDNA Panel

Placenta
Right Ventricle
Left Ventricle
Right Atrium
Left Atrium




Figure 28

Immunohistochemical Staining of Mas in Human Left Ventricular Sections




Figure 29

Constitutive Mas Gq Activity for Human and Rat Receptor Constructs




Figure 30

Mas Agonist and Inverse Agonists Modulate Gq in HEK293 Cells Expressing Human Mas




Figure 31

Mas Agonist and Inverse Agonists Modulate Gq in HEK293 Cells Expressing Rat Mas




Figure 32

Effect of Mas Agonist on Intracellular Ca^{2+} Levels




Figure 33

Mas Agonist-Mediated Decrease in Coronary Flow is Mas Receptor Dependent




Figure 34




Figure 35

Effects of Mas Compounds on Rat Coronary Flow after Ischemia and Reperfusion




Figure 36

Ablation of Mas Receptor in Mice is Cardioprotective during I/R Injury




Figure 37

Inverse Agonist of the Mas Receptor AR244555 was Cardioprotective in Rats when Administered prior to Ischemia or Immediately Before Reperfusion




Figure 38

Expression of Mas Receptor Following LPS Stimulation




Figure 39




Figure 40




Figure 41




Figure 42

Protocol for Left Kidney Artery Ischemia Reperfusion Injury




Figure 43

Compound 170 Improves Kidney Function Compared to Vehicle Treatment
as Measured by Blood Creatinine




Figure 44

Compound 170 Improves Kidney Function Compared to Vehicle Treatment
as Measured by BUN




Figure 45

Protocol for Transient Cerebral Ischemia/Stroke Rat Model




Figure 46

Compound 170 Reduced Brain Damage Associated with
Transient Ischemic Injury in the Rat




Figure 47